Remove Healthcare Remove Pharmaceutical manufacturing Remove Prescription
article thumbnail

Should we be worried about pharma’s supply chain?

World of DTC Marketing

The US Food and Drug Administration (FDA) believes the adulteration of heparin was an economically motivated act—a clear breach of the US pharmaceutical supply chain. The answer lies in both an outdated way we develop prescription drugs and the continued quest for the next big blockbuster. In other words, money over safety.

article thumbnail

10 New Solutions, Strategies, and Devices to Boost Adherence

PM360

One reason for this growth is an increasing demand for personalized healthcare technologies as patients look for advances in how healthcare is delivered following the pandemic. Unlike other formulary optimization solutions, Levrx delivers plan-specific and real-time prescription insights. billion in 2030 at a CAGR of 9.2%.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

MEDICAL ADHERENCE – Tapping Into Provider-Patient Bonds

PM360

Improving our collective understanding of the patient’s overall healthcare experience is necessary to effectively deliver prescription support. How can we ensure that vital prescription information reaches patients when they need it? Where and how you message HCPs and patients must synchronize with when they are engaged.

Medical 52
article thumbnail

A Powerful Point-of-Sale Partnership that Delivers on the Promise of Affordable Insulin

PM360

In March of this year the three largest insulin manufacturers announced a dramatic reduction in the price of many commonly prescribed insulins and a monthly out-of-pocket (OOP) cap of $35 that went into effect in May. The price is available to cash-paying patients with a valid prescription. for only $35. References: 1.

Retail 52
article thumbnail

Affordability Programs Need a Technology Makeover

PM360

The cost of filling a prescription can keep 21% of patients from getting an Rx, and one in ten patients will modify their treatment plan because of cost, according to recent polling data from KFF. When treatments are missed or reduced, health outcomes suffer.

article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation. Actavis, 570 U.S. 136 (2013), [link] opinions/12pdf/12-416_m5n0.pdf.

article thumbnail

Diversity and inclusion in oncology clinical trials

Clarify Health

With the myriad of guidance and recommendations to boost diversity and inclusion in oncology trials, , biotech and pharmaceutical manufacturers are left to interpret the criteria and implement them through tangible action. Clarify launched its real-world evidence on health disparities in 2021.